Form 4: Lyra Therapeutics Director, Nancy Lynn Snyderman, Reports Stock Option Grant

Nancy Lynn Snyderman, a director of Lyra Therapeutics, reported the acquisition of stock options.

Summary

• On June 13, 2024, Nancy Lynn Snyderman, a director of Lyra Therapeutics, Inc. (LYRA), reported a transaction.
• Snyderman acquired 30,000 stock options with an exercise price of $0.31.
• These options vest on the earlier of June 13, 2025, or the day before the next annual meeting of stockholders after the grant date, contingent on continued service as a non-employee director.
• Following the transaction, Snyderman directly owns 30,000 derivative securities (stock options).

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard reporting of stock option grants to a director.

Positives

• The grant of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board.

Industry Context

Form 4 filings are standard practice for reporting changes in beneficial ownership by company insiders, providing transparency to investors.

Stakeholder Impact

• The stock option grant aligns the director's interests with shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates

Keywords

Lyra Therapeutics, Director, Stock Options, Form 4, Beneficial Ownership, Snyderman, LYRA